63 results on '"Calés P"'
Search Results
2. Actualités sur les co-infections VIH–VHC
3. Fibrinogen angers with a new deletion (γ GVYYQ 346‐350) causes hypofibrinogenemia with hepatic storage
4. Physiopathologie de la cirrhose et de ses complications
5. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel
6. Diagnostic et quantification de la fibrose hépatique par IRM de diffusion : résultats préliminaires
7. Diagnostic des hépatopathies et de leur sévérité
8. The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI
9. Personalized platelets/liver stiffness ratio improves and secures the screening of esophageal varices needing treatment
10. SAT-227 - Non-selective beta-blockers increase liver mortality when MELD is ≥12 in a prospective 5-year follow-up cohort of alcoholic cirrhosis
11. SAT-067 - Reliability criteria for liver stiffness measurement with ARFI
12. FRI-475 - The easy Liver Fibrosis Test (eLIFT) avoids unnecessary specialized evaluations of liver fibrosis in NAFLD and ALD patients
13. SAT-477 - Liver Fibrosis Diagnosis by Blood Test and Elastography: Agreement or Combination?
14. SAT-029 - Evaluation and Improvement of Baveno 6 Recommendation for Non-Invasive Diagnosis of Esophageal Varices
15. SAT-007 - The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)
16. FRI-303 - Non-Invasive Tests for the Diagnosis of Liver Fibrosis are also Prognostic Markers in Non-Alcoholic Fatty Liver Disease
17. THU-352 - Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)
18. PS116 - Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)
19. PS088 - New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)
20. P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study
21. P0989 : A combination of elastometry and blood markers improves the non-invasive staging of liver fibrosis in NAFLD
22. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic
23. P0511 : Direct comparison of 3 elastrometry devices (fibroscan, acoustic radiation force impulse, supersonic shearwave imaging) for the non-invasive diagnosis of liver fibrosis in chronic liver diseases
24. P0509 : Diagnostic and prognostic stagings are improved by multi-targeting biomarkers. Application to liver fibrosis tests
25. Intrafamilial hepatitis E in France
26. P.271 Early HCV viral load determination as a predictive parameter of the response to the antiviral therapy in HCV infected patients
27. CA20 - Description affinée de la vitesse de progression de la fibrose hépatique par la morphométrie
28. C08 - Diagnostic de l’hémorragie par rupture de varices et de son contrôle au cours de la cirrhose
29. Interet de l’IRM pour la mesure du debit sanguin azygos chez le patient cirrhotique : evaluation de la reponse pharmacologique
30. Existe-t-il des marqueurs sanguins de fibrose hépatique utilisables en pratique clinique ?
31. CA 40-Effets hémodynamiques de la noradrénaline et de la synephrine dans un modele d’hypertension portale chez le rat
32. CA 19-Méta-analyse des scores sanguins de fibrose hépatique au cours des hépatites chroniques C
33. CA 20-Performance diagnostique des tests sanguins de fibrose hépatique pour la fibrose sévère et la cirrhose
34. CA 18-Association scores sanguins, écho-doppler et élastométrie impulsionnelle pour le diagnostic de fibrose hépatique
35. CA 3-Expression hépatique endogène du symporteur sodium iodure (NIS) et inhibition de la croissance tumorale après radiothérapie à l’IODE 131
36. CO 15-Méta-analyse des scores sanguins de fibrose hépatique (fibromètre, hepascore, APRI) au cours des hépatopathies alcooliques
37. CO 7-Réponse anti-virale de l’albumine interféron alfa-2B en association A la ribavirine chez les malades infectés par le VHC de génotype 1 naïfs de traitement anti-VHC
38. CA2 - Causes de variabilité des scores histopathologiques des hépatites chroniques virales
39. CA1 - Évaluation non invasive des caractéristiques de la fibrose hépatique
40. CO28 - Étude de l’architecture de la fibrose hépatique humaine par analyse fractale
41. Apoptosis and liver fibrosis: antifibrotic strategies
42. Effect of propranolol on metabolic activity of the liver in patients with alcoholic cirrhosis
43. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: Interim analysis of a double-blind multicentre randomized trial
44. Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with liver cirrhosis
45. Noninvasive diagnosis of hepatic fibrosis or cirrhosis
46. Survenue d'un lymphome non hodgkinien au cours d'une hépatite chronique virale C
47. Anticorps anti-plaquette: rôle dans la thrombopénie des hépatopathies?
48. Factors associated with first bleeding and death among cirrhotic patients treated by betablockers. Analysis of 589 cases included in four trials
49. Factor predictive of a response to interferrcn cherapy in NANB chronic active hepatitis
50. Systemic and splanchnic hemodynamic effects of molsidomine in rats with CCL4 induced cirrhosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.